Kura Oncology Reports Second Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Kura Oncology (KURA) Tops Q2 EPS by 11c, Beats on Revenue
August 12, 2026 4:05 PM EDTKura Oncology (NASDAQ: KURA) reported Q2 EPS of ($0.77), $0.11 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $20.87 million versus the consensus estimate of $20.16 million.
For earnings history and earnings-related data on Kura Oncology (KURA) click here.
... More